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Abstract:
Background: Sublingual nitroglycerin increases exercise duration in patients with stable angina. Brief results from this study were 
published previously in German. Here, we more fully describe the study methodology, patient characteristics, and detailed results.
Methods: This double-blind, crossover study enrolled 51 patients with stable angina. Patients were randomized to 1 of 5 treatment 
sequences and were administered placebo or nitroglycerin spray (0.2 mg, 0.4 mg, 0.8 mg, or 1.6 mg). Patients carried out 1 control 
exercise tolerance test (ETT) and 1 investigational ETT at each visit.
Results: Dose-dependent increases in time to onset of angina, time to onset of moderate angina, and the occurrence of a minimum 
1.0-mm ST-segment depression were seen following administration of nitroglycerin spray.
Conclusions: These results support the use of sublingual nitroglycerin spray in patients with stable angina who are being managed with 
medical therapy and in patients who have persistent angina post-revascularization.
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Introduction
Patients with frequent angina ($1 episode per week) 
report  greater  physical  limitations  and  decreased 
quality of life compared with patients with minimal 
angina.1 The goals of chronic stable angina manage-
ment are not only to control symptoms, but also to 
reduce the risk of adverse clinical outcomes.2–6 As 
symptom control impacts the patient’s quality of life, 
maximum consideration should be given to the array 
of available management options that aim to reduce 
angina  symptoms.  For  many  patients,  this  would 
include a physical activity program aimed at improv-
ing  exercise  tolerance  in  accordance  with  current 
secondary prevention guidelines.
Angina management options include anti-anginal 
drugs and coronary artery revascularization. Several 
studies  have  shown  that  optimal  medical  therapy, 
along with aggressive risk factor modification, is as 
effective as revascularization in reducing the risk of 
adverse coronary events.7–9 Optimal medical therapy 
includes anti-anginal or anti-ischemic as well as dis-
ease-modifying therapy.8,10 The anti-ischemic agents 
include short- and long-acting nitrates, beta-blockers, 
and calcium channel blockers.3,4,11 These agents reduce 
angina symptoms and prolong exercise duration and/
or time to ST-segment depression.3,11 Frequently, a 
combination of drugs is necessary for optimal symp-
tom control.3 Nitrates work primarily by venodila-
tion and afford rapid relief of angina.12 A number of 
  placebo-controlled studies have shown that the sub-
lingual application of nitroglycerin increases exercise 
duration in patients with stable angina.13–17
Published data also suggest that residual and recur-
rent angina is frequently experienced by patients who 
have already undergone either a percutaneous or sur-
gical revascularization procedure, and these patients 
require  continued  medical  therapy  with  multiple 
anti-anginal agents, including short- and long-acting 
nitrates, for control of their symptoms.8,18,19 Increased 
physical exercise is also important in patients with 
stable  angina  to  reduce  the  risk  of  cardiovascular 
events, and current recommendations call for the use 
of sublingual nitroglycerin as part of optimal medical 
therapy.5,20
This randomized, double-blind, placebo-controlled, 
crossover, dose-ranging multicenter study in patients 
with chronic stable angina evaluated the effect of a 
sublingual nitroglycerin spray formulation on time to 
onset of angina during exercise, total exercise duration, 
and time to exercise-induced myocardial ischemia, 
as  evidenced  by  electrocardiographic  ST-segment 
depression. Brief results were previously published 
in German.21 The goal of the present article is to more 
fully describe the study methodology, patient charac-
teristics, and detailed results in the context of current 
optimal medical therapy.
Methods
Study approval and consent
This study was carried out at four centers in the United 
States and conducted in accordance with the Interna-
tional Conference on Harmonisation Guidelines for 
Good Clinical Practice and Food and Drug Adminis-
tration guidelines. The study was approved by local 
Investigational Review Boards. All patients provided 
written informed consent at the screening visit, prior 
to starting any study-related procedures.
Patients
Adults ($18 years of age) with coronary artery dis-
ease as documented by a $50% reduction in arterial 
lumen diameter in 1 or more major coronary arteries 
or their primary branches, a previously documented 
myocardial infarction, or reversible perfusion defect 
on  stress  thallium-201  scintigraphy  and  a  diagno-
sis of chronic stable exertional angina that had been 
made at least 2 months prior to screening were eli-
gible to be screened. In the 2 months prior to study 
entry, patients were required to have been on a stable 
medical treatment regimen for their angina. Patients 
with  unstable  angina,  myocardial  infarction,  coro-
nary angioplasty, or cardiac surgery within 3 months 
of  screening  were  excluded.  Additional  exclusion 
criteria included a history of congestive heart failure 
(NYHA III or IV), significant disease of the cardiac 
conduction  system,  uncontrolled  hypertension  or 
hypotension, any physical conditions known to affect 
ST-segment morphology, or severe organ damage or 
disease of any system. Patients were not permitted to 
receive concomitant therapy with long-acting nitrates 
or digitalis preparations during the study. In addition, 
participation in an investigational drug study within 
1 month prior to the screening visit or while partici-
pating in the study was prohibited. Patients with clini-
cally significant deviations from normal in either the 
physical exam or lab parameters and patients with effect of sublingual nitroglycerin spray on exercise capacity and myocardial ischemia in angina pectoris 
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peripheral arterial disease that limited their exercise 
capacity were also excluded.
Study Design and Treatment
According to the approved protocol, each center was 
to enroll a minimum of 12 patients to ensure eval-
uable outcomes for 40 patients at the end of study. 
Following an initial screening visit, eligible patients 
returned for a baseline exercise tolerance test (ETTB) 
according to a standard Bruce protocol.22 Of note, 
exercise testing is associated with minimal compli-
cations; death and myocardial infarction occur at a 
rate of #1 per 2,500 tests performed.15,23 Patients who 
developed angina within 3–9 minutes of commenc-
ing exercise were eligible to continue in the study. 
Following  a  90-minute  rest  period,  these  patients 
were assessed for nitrate response. Patients who were 
able to exercise for $60 seconds longer in this ETT 
(ETTRES) than in the ETTB were eligible to continue in 
the study. At their next visit, patients completed a con-
firmatory ETT (ETTCONF) to establish reproducibility 
(within 20%) of the time to development of moder-
ate angina when compared to the ETTB. In order to 
reduce baseline variability, all ETTs were carried out 
at approximately the same time of day. Non–study-
related  sublingual  nitroglycerin  was  discontinued 
6 hours prior to testing, while other anti-anginal med-
ications were discontinued approximately 24 hours 
prior to each visit.
After baseline and confirmatory ETTs were com-
pleted, patients were randomized to 1 of 5 treatment 
sequences (Fig. 1). The goal of this crossover study 
design with each patient serving as his/her own control 
was to minimize the impact of any training effect on 
the mean values for each treatment dose. The crossover 
period consisted of 5 additional visits within 14 days, 
at which patients were administered placebo or sub-
lingual nitroglycerin spray (0.2 mg, 0.4 mg, 0.8 mg, or 
1.6 mg; Nitrolingual Pumpspray, G. Pohl-Boskamp 
GmbH & Co. KG, Germany). In order to minimize the 
impact of any training effect, patients completed a con-
trol ETT (ETTC) and an investigational ETT (ETTINV) 
at each visit. ETTC studies were carried out at approxi-
mately the same time of day as the introductory ETT 
studies (ETTB and ETTCONF). Following a 90-minute 
rest period, study medication was administered and 
then ETTINVs commenced within 2–5 minutes.
Outcomes
Primary  efficacy  endpoints  were  time  to  onset  of 
angina symptoms and time to development of moder-
ate angina (defined as the level of activity at which the 
patient would normally stop activity). The secondary 
endpoint was time to 1-mm ST-segment depression 
(myocardial ischemia). To minimize the impact of any 
training effect, efficacy endpoints are described as the 
mean difference between ETTINV and ETTC at each 
visit. The difference between the confirmation and 
baseline ETTs was then subtracted from this value to 
further reduce the impact of any training effect.
Safety  parameters  included  evaluation  of  all 
changes in physical examination, vital signs, ECG, 
and laboratory evaluations. All adverse events experi-
enced during the study were summarized.
Patient selection
Visit 1
Screening Selection
ETTB ETTRES ETTCONF ETTC ETTINV ETTC ETTINV ETTC ETTINV ETTC
b b b b a b
ETTINV ETTC ETTINV
Confirmation
Randomization Double-blind phase
Visit 2V isit 3
Group A
Group B
Group C
Group D
Group E
Visit 5 Visit 4
Placebo
0.8 mg
0.8 mg
0.4 mg
0.4 mg
1.6 mg
1.6 mg
0.2 mg
0.8 mg
0.4 mg
1.6 mg
1.6 mg
1.6 mg
0.2 mg 0.8 mg
0.4 mg 0.8 mg
0.4 mg 0.2 mg
0.2 mg
0.2 mg
Placebo
Placebo
Placebo
Placebo
Visit 6 Visit 7 Visit 8
Figure 1. Study design.
notes: aThe baseline eTT was followed by a 90-minute rest period before the nitrate response eTT was performed; bthe control eTT was followed by a 90-minute 
rest period before the investigational eTT was performed. The investigational eTT was carried out within 2–5 minutes of study drug administration.
Abbreviations: eTTB, Baseline exercise tolerance test (treadmill); eTTreS, nitrate response exercise tolerance test (treadmill); eTTCOnF, Confirmation 
exercise tolerance test (treadmill); eTTC, Control exercise tolerance test (treadmill); eTTInV, Investigational exercise tolerance test (treadmill).Thadani and Wittig
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Results
Patient characteristics
Of the 61 patients assessed for eligibility, 10 patients 
did not meet the protocol criteria and were therefore 
excluded.  A  total  of  51  patients  performed  the 
baseline exercise test and qualified for continuation. 
Following  a  90-minute  rest  period,  patients 
underwent a subsequent stress test after receiving 
0.4  mg  of  open-label  sublingual  nitroglycerin 
spray. All 51 patients showed an improvement in 
exercise duration of 60 seconds or greater (range 
1.02–4.7 minutes).
A total of 51 patients between the ages of 34 and 
77  years  continued  in  the  double-blind  phase  and 
were  randomized  to  1  of  5  treatment  sequences. 
Figure 2 provides a flow diagram of patient disposi-
tion over the study period. Two patients did not com-
plete the study (1 patient was lost to follow-up and 
1 patient discontinued prematurely due to ventricular 
tachycardia/fibrillation requiring cardioversion after 
the control exercise test at Visit 5; this event was 
not considered to be treatment related). The remain-
ing 49 patients completed all portions of the study. 
Overall patient characteristics including angina and 
cardiovascular event history, along with concomitant 
medications, are described in Table 1.
Efficacy
A  dose-dependent  increase  in  time  to  onset  of 
  moderate angina was seen following administration 
of nitroglycerin spray (Table 2, Fig. 3). In addition, 
the time to onset of angina was significantly higher 
in all treatment groups (0.2 mg, 0.4 mg, 0.8 mg, and 
1.6 mg) than in the placebo group (Table 2, Fig. 4). 
The increase in time to onset of angina and to onset of 
moderate angina was most pronounced in the 1.6-mg 
group, with dose linearity between 0.4- and 1.6-mg 
doses  of  nitroglycerin  spray.  The  occurrence  of  a 
  minimum 1.0-mm ST-segment depression was later in 
all treatment groups (0.2 mg, 0.4 mg, 0.8 mg, 1.6 mg) 
compared with the placebo group (Table 2, Fig. 5).
Safety
Overall, nitroglycerin spray was generally well toler-
ated. Of 51 patients, 12 (24%) reported adverse events 
at the qualification visit (open-label sublingual nitro-
glycerin response test). These primarily consisted of 
mild headache (n = 9).
-A dverse event  N = 1 
- Lost to follow up  N = 1 
N = 49
Total number of patients
completing study 
Drop-outs: N = 2 (3.9%)
Screening
N = 61
Assessed for eligibility
Excluded: N = 10 (16.4%)
End of study
Eligibility
Nitrate response
Randomization
Double-blind phase
N = 51
Eligible patients
N = 51
Positive nitrate response
N = 51
Randomized patients
N = 51
Treated patients
Figure 2. Patient disposition.effect of sublingual nitroglycerin spray on exercise capacity and myocardial ischemia in angina pectoris 
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Adverse  events  considered  related  to  treatment 
were reported for 2 (4%), 4 (8%), 8 (16%), 9 (18%), 
and 13 (26%) patients receiving placebo and 0.2 mg, 
0.4  mg,  0.8  mg,  and  1.6  mg  nitroglycerin  spray, 
respectively. The most frequently reported adverse 
events of this nature were headache and dizziness, all 
of which were mild to moderate in severity. The inci-
dence of treatment-related adverse events was dose 
dependent, with the incidence of headache increasing 
from 0 with placebo to 3 (6%), 5 (10%), 6 (12%), and 
8 (16%) after 0.2 mg, 0.4 mg, 0.8 mg, and 1.6 mg 
nitroglycerin spray, respectively. No serious adverse 
events related to treatment were reported.
Per protocol, patients with systolic blood pressure 
(SBP) less than 100 mmHg were excluded from the 
study. Symptomatic hypotension was not reported as 
an adverse event, however SBP decreased to a level 
of 100 mmHg or less in 1 (2%), 0 (0%), 1 (2%), 0 
(0%), and 3 (5%) patients after receiving placebo and 
0.2 mg, 0.4 mg, 0.8 mg, and 1.6 mg nitroglycerin 
spray in the double-blind phase.
Discussion
Lifestyle  modifications,  including  supervised  exer-
cise therapy, play an important role in the success of 
optimal medical therapy.24–27 However, patients with 
stable angina generally have impaired exercise toler-
ance and reduced daily physical activity.28 Sublingual 
nitroglycerin  increases  physical  exercise  tolerance 
which, in turn, helps to increase the amount of exertion 
possible prior to the onset of angina.12,13 Sublingual 
forms of nitroglycerin are readily absorbed through 
mucous membranes, and their effect is prompt, reli-
able, and more effective than other forms of nitro-
glycerin, including ointments, transdermal patches, 
and  sustained-release  preparations.11,29  The  results 
of this study are in line with prior findings and dem-
onstrate a significant improvement in exercise toler-
ance with sublingual nitroglycerin spray in patients 
with stable angina. Although sublingual nitroglycerin 
spray  was  generally  well  tolerated,  an  increase  of 
treatment-related adverse events was observed with 
higher dose levels (26% of patients with 1.6 mg nitro-
glycerin spray).
One  important  issue  that  is  not  specifically 
addressed in this study is the clinical relevance of the 
nearly 1-minute improvement in exercise duration 
with  sublingual  nitroglycerin  spray  over  placebo. 
Table 1. Patient characteristics (n = 51).
Gender, n 
  Male 
  Female
 
39 
12
Age, years (median [min–max]) 65 (34–77)
Race, n 
  Caucasian 
  hispanic 
  Asian 
  Black
 
38 
11 
1 
1
Height, cm (mean) 172.2
Weight, kg (mean) 81.7
Angina history, years  
(median [min–max])
6 (0–23)
Angina attacks 
  Duration, minutes (mean [min–max]) 
  Attacks/week, no. (mean [min–max]) 
    nTg sprays/week, no.  
(mean [min–max])
  Severity of attacks 
    Mild 
    Moderate
 
2.7 (1.0–10.0) 
4.9 (1–35) 
4.25 (0–35) 
 
 
30 
19
History of cardiovascular events, n 
  Myocardial infarction 
  PTCA 
  Bypass surgery
 
23 
12 
12
concomitant study medication, %
Disease-modifying therapy
Aspirin
  Primary prevention 64
  Secondary prevention 65
Statins
  Primary prevention 25
  Secondary prevention 17
ACe inhibitors
  Primary prevention 7
  Secondary prevention 13
Beta blockers
  Primary prevention 25
  Secondary prevention 26
symptomatic treatment for angina/ischemia control
Calcium antagonists
  Primary prevention 82
  Secondary prevention 87
Sublingual nTg spray
  Primary prevention 79
  Secondary prevention 87
Sublingual nTg tablets
  Primary prevention 11
  Secondary prevention 9
Other relevant medications
  Anti-hypertensives 29
  Diabetes medication 26
Abbreviations:  nTg,  nitroglycerin;  PTCA,  percutaneous  transluminal 
coronary angioplasty.Thadani and Wittig
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Figure 4. Adjusted mean change in time to onset of angina.a
notes: aInvestigational eTT minus control eTT; sublingual nitroglycerin 
spray versus placebo; bP  0.05; cP  0.001.
Abbreviation: nTg, nitroglycerin.
Table 2. exercise tolerance time following administration of nitroglycerin spray.
Adjusted mean change  
in time to onset of  
moderate angina (min)a
Adjusted mean change  
in time to onset of  
angina (min)a
Adjusted mean change  
in time to onset of 1-mm  
sT-segment depression (min)a
Placebo 0.49 0.61 0.19
0.2 mg nTg 0.88c 1.12b 0.93b
0.4 mg nTg 0.87c 1.05b 0.8
0.8 mg nTg 1.13d 1.37d 1.26c
1.6 mg nTg 1.26d 1.47d 1.59c
notes: aInvestigational eTT minus control eTT; sublingual nitroglycerin spray versus placebo; bP  0.05; cP  0.01; dP  0.001.
Abbreviation: nTg, nitroglycerin.
It must be recognized that this improvement was expe-
rienced by patients who were exercising at a higher 
work load (higher speed and incline during the tread-
mill test) after receiving the study medication. As 
most real-world patients have a much slower walking 
pace, this finding indicates that prophylactic nitro-
glycerin spray might allow much greater increases 
in  walking  times  during  normal  daily  activities. 
Although this outcome was not formally evaluated 
in the present study or discussed in previous publica-
tions to our knowledge, patients have often reported 
a marked increase in angina-free walking time and 
exercise  duration  after  taking  prophylactic  sublin-
gual nitroglycerin.
Additional considerations
Since  this  study  of  sublingual  nitroglycerin  spray 
was conducted, there have been significant changes 
in optimal medical therapy for stable coronary artery 
disease. This is particularly apparent in the greater 
use of beta-blockers compared with calcium chan-
nel blockers and long-acting nitrates to treat angina, 
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Figure 3. Adjusted mean change in time to onset of moderate angina.a
notes: aInvestigational eTT minus control eTT; sublingual nitroglycerin 
spray versus placebo; bP  0.01; cP  0.001.
Abbreviation: nTg, nitroglycerin.
and the routine use of daily aspirin and a statin to 
reduce serious cardiovascular outcomes.3,8 Although 
beta-blockers  are  currently  considered  a  standard 
treatment for stable angina, patients receiving these 
medications  may  continue  to  experience  angina.30 
However, patients with a history of beta-blocker use 
who are appropriately supplemented with sublingual 
nitroglycerin or long-acting nitrates show significant 
improvements in angina-free exercise duration and 
total walking time compared with placebo.3,5,29
The  American  College  of  Cardiology  and 
American  Heart  Association  guidelines  for  the 
management of patients with chronic stable angina 
emphasize the initial use of medical therapy.5,20,31 
These guidelines include the recommendation for 
all  patients  to  undergo  a  risk  assessment  with  a 
physical activity history and/or an exercise test to 
guide prognosis and prescription. ETT is associated 
with a very low rate of serious adverse events such 
as death (0.5 per 10,000 tests), myocardial infarction 
(3.58  per  10,000  tests),  or  serious  arrhythmias 
(4.78  per  10,000  tests).15  Guideline-compliant effect of sublingual nitroglycerin spray on exercise capacity and myocardial ischemia in angina pectoris 
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and  optimal  medical  therapy  groups,  respectively, 
angina-free after 5 years of follow-up.8 Further analysis 
of data from the COURAGE study found that both 
groups of patients had marked improvements in health 
status, including reductions in angina symptoms, and 
improved  quality  of  life. Although  the  PCI  group 
demonstrated  significantly  greater  health  benefits 
in  the  short  term,  these  benefits  disappeared  after 
longer-term follow-up, and by 36 months there was 
no significant difference in health status between the 
2 groups.9 The Bypass Angioplasty Revascularization 
Investigation 2 Diabetes trial in patients with diabetes, 
coronary artery disease, and classic angina compared 
the effects of revascularization with medical therapy 
alone  on  clinical  outcomes.  During  the  5-year 
follow-up,  no  difference  was  found  between  the 
medical  therapy  and  revascularization  groups  on 
the  risk  of  all-cause  death,  myocardial  infarction, 
or  stroke.34  Furthermore,  a  meta-analysis  of  11 
randomized trials comparing PCI with conservative 
treatment  in  patients  with  stable  coronary  artery 
disease found no significant difference between the 2 
treatment strategies with regard to overall mortality, 
cardiac death, or myocardial infarction.7
Current  recommendations  state  that  patients 
with stable angina may defer surgical intervention 
without  additional  risk  to  allow  for  determination 
of response to optimal medical therapy.5,11 Despite 
the  published  outcome  data  and  current  guideline 
recommendations, many patients are still referred for 
revascularization, mainly due to a belief that these 
procedures reduce the risk of myocardial infarction or 
death more effectively than optimal medical therapy 
alone.2,3,8,35  Additional  studies  assessing  the  long-
term benefits of exercise in the context of medical 
therapy compared with revascularization outcomes 
could  help  to  further  inform  the  clinical  decision 
making process.
conclusions
In this study, sublingual nitroglycerin spray was shown 
to  increase  time  to  onset  of  moderate  angina  dur-
ing exercise. This improvement in physical exercise 
tolerance may be of great clinical relevance, as the 
prophylactic  use  of  sublingual  nitroglycerin  spray 
allows patients to face exertion with confidence and 
permits exercise for a longer amount of time. These 
results  support  the  use  of  sublingual  nitroglycerin 
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Figure 5. Adjusted mean change in time to onset of 1-mm ST-segment 
depression.a
notes: aInvestigational eTT minus control eTT; sublingual nitroglycerin 
spray versus placebo; bP  0.05; cP  0.01.
Abbreviation: nTg, nitroglycerin.
medical therapy improves clinical outcome in many 
patients  with  stable  angina,  as  evidenced  by  an 
observational study in which increasingly guideline-
compliant therapy was associated with a reduction 
in  death  and  myocardial  infarction  in  patients 
with  stable  angina  during  1  year  of  follow-up.32 
Indeed, implementation of a quality improvement 
program  in  Utah  to  enhance  the  prescription  of 
appropriate discharge medications among patients 
with  cardiovascular  disease  was  associated  with 
improvements in cardiovascular readmission rates 
and reductions in mortality.33
A number of studies have compared the effect of 
optimal medical therapy versus revascularization on 
symptoms and outcomes in patients with coronary 
artery  disease  and  stable  angina.  In  general,  these 
studies have shown that optimal medical therapy is 
effective  in  controlling  symptoms  and,  along  with 
risk factor modification, can reduce the risk of adverse 
cardiac  events.8,34  Moreover,  these  studies  have 
shown that there is no significant difference in serious 
adverse clinical events, such as myocardial infarction 
and  death,  between  patients  who  have  received 
medical  therapy  and  those  who  have  undergone 
revascularization.2,5,8  The  Clinical  Outcomes 
Utilizing  Revascularization  and  Aggressive  Drug 
Evaluation (COURAGE) trial, which compared the 
efficacy of percutaneous coronary intervention (PCI) 
plus optimal medical therapy versus optimal medical 
therapy alone, demonstrated similar rates of death and 
nonfatal myocardial infarction in both patient groups 
over a follow-up period of 55 months.8 Moreover, both 
groups demonstrated a substantial reduction in angina 
symptoms, with 74% and 72% of patients in the PCI Thadani and Wittig
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spray as nitrate therapy in patients with stable angina 
who are being managed with optimal medical therapy. 
This approach may also be beneficial for patients who 
have persistent angina post-revascularization. Further 
studies are needed to evaluate the long-term benefi-
cial effects of using routine prophylactic nitroglyc-
erin spray in patients with stable angina to increase 
exercise  duration  and  improve  quality  of  life  and 
well-being.
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